Technology ID
TAB-2742
Virus Microneutralization Assay Data Analysis for Vaccine Development, Enhancement and Efficacy Improvement
E-Numbers
E-262-2013-0
Lead Inventor
Schiffer, Jarad (CDC)
Co-Inventors
Hancock, Kathy (CDC)
Applications
Vaccines
Therapeutics
Software / Apps
Research Materials
Occupational Safety and Health
Diagnostics
Consumer Products
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Pre-Clinical (in vitro)
Development Status
- In vitro data available
- In situ data available (on-site)
Research Products
Research Equipment
Computational models/software
Antibodies
Lead IC
CDC
ICs
CDC
This CDC generated invention entails improved methods of analyzing microneutralization assays, especially for the purposes of determining specific antibody concentrations and optimizing vaccine formulation. More specifically, the invention is a set of SAS based programs using 4-parameter logistic curve fitting algorithms to interpolate between individual data points, allowing for enhanced accuracy and precision when establishing neutralization titers. This method allows every experiment to be analyzed the same way, provides greater accuracy by interpolating curve fits between dilutions, prevents transcription errors or manual calculation errors, develops and applies consistent quantitative control rules, and improves operational speed and efficiency.
Commercial Applications
- Commerical virus vaccine evaluation and strain selection
- Virus strain surveillance programs
- Harmonize data analysis and standardize reporting procedures for improved worldwide, health-programs cohesion
Competitive Advantages
- Demonstrated improvements in accuracy and precision calculating virus microneutralization titers
- Programs produce structured datasets allowing for rapid report generation and high-level analyses
- Useful for improved strain selection in future influenza (or other) vaccine development
Licensing Contact: